Related Experiment Videos

Genetic polymorphisms and the risk of stroke after cardiac surgery

Hilary P Grocott1, William D White, Richard W Morris

  • 1Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA. h.grocott@duke.edu

Stroke
|July 30, 2005
PubMed

Insights

Genetic variants in C-reactive protein (CRP) and interleukin-6 (IL-6) are linked to increased stroke risk after cardiac surgery. This finding highlights inflammation

Area of Science:

  • Cardiovascular Surgery
  • Genetics
  • Neurology

Background:

  • Stroke is a major complication following cardiac surgery.
  • Genetic factors influencing post-cardiac surgery stroke risk are not fully understood.
  • Inflammation plays a role in cardiovascular disease and stroke.

Purpose of the Study:

  • To investigate the association between specific genetic polymorphisms and stroke risk in patients undergoing cardiac surgery.
  • To test the hypothesis that genetic variants increase the likelihood of stroke after cardiopulmonary bypass surgery.

Main Methods:

  • Studied 1635 patients undergoing cardiopulmonary bypass surgery.
  • Analyzed DNA for 26 single-nucleotide polymorphisms (SNPs).
  • Used multivariable logistic regression and permutation analysis to assess genetic and clinical associations with stroke.

Main Results:

  • A combination of minor alleles in C-reactive protein (CRP; 3'UTR 1846C/T) and interleukin-6 (IL-6; -174G/C) polymorphisms was significantly associated with stroke (OR, 3.3; P=0.0023).
  • This association remained significant after adjusting for age in multivariable analysis (P=0.0020).
  • The combined genetic variant occurred in 35.7% of patients and was linked to a 1.7% stroke incidence.

Conclusions:

  • Common genetic variants in CRP and IL-6 are significantly associated with post-cardiac surgery stroke risk.
  • These findings suggest a crucial role for inflammation in the development of stroke after cardiac procedures.
  • Identifying at-risk individuals through genetic markers could inform preventative strategies.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...